Cornerstone BioPharma has added Ascend Therapeutics as a partner in the promotion and sale of the drug Balacet 325.

The mild-to-moderate pain killer was approved by the Food and Drug Administration in 2005.

“We are confident in this strategic move for Balacet 325,” said Craig Collard, chief executive officer of Cornerstone BioPharma, Inc. “It will not only increase Cornerstone’s reach and penetration in our current markets, but will provide the opportunity for us to expand into women’s health.”